Abstract：
A combination of azacitidine and venetoclax (AZA-VEN) has been approved for the treatment of adult treatment-naïve acute myeloid leukemia (AML) patients, ineligible for intensive chemotherapy. The protocol may also constitute an alternative for the treatment of patients with mixed phenotype acute leukemia (MPAL), for which no established treatment guidelines exist. It may be anticipated, that alike in AML or chronic lymphocytic leukemia, the treatment of MPAL may be complicated by the tumor lysis syndrome (TLS). No case of TLS in MPAL after VEN has been however reported so far. Here, we present a case of a patient with MPAL, who received AZA-VEN. The patient had a substantial bulk of disease with generalized lymphadenopathy and increased white blood cell count. Despite preventive measures, the patient developed the clinical TLS, which was successfully treated. Based on the current case and other published cases, the incidence of TLS after AZA-VEN was established at 17%.
摘要：
阿扎胞苷和维奈托克（AZA-VEN）的组合已被批准用于治疗成人初治急性髓细胞性白血病（AML）患者，没有资格接受强化化疗。该方案也可能构成治疗混合表型急性白血病（MPAL）患者的替代方案，没有既定的治疗指南。可以预见，类似于AML或慢性淋巴细胞白血病，肿瘤溶解综合征（TLS）可能会使MPAL的治疗复杂化。然而，到目前为止，没有报道VEN后MPAL中的TLS病例。这里,我们介绍了一例MPAL患者,谁收到了AZA-VEN。该患者患有大量疾病，伴有全身淋巴结病和白细胞计数增加。尽管采取了预防措施,患者开发了临床TLS，已成功治疗。根据目前的案例和其他已公布的案例，AZA-VEN术后TLS发生率为17%.
